General Posters
Digital Poster screens - Hall 3
Screens 1 - 10: Poster Tours
Screens 11 - 20: General Posters
Screen 11: Epilepsy / General Acute / General Autonomic
1 Fadi Ahmed: Frontal Lobe Epilepsy Secondary To Left Cranial Osteoma And a Mucocele
2 Siddharth Kamath: Supporting Quality And Quantity: Identifying Target Areas for Improvement of Home Video in Epilepsy Diagnosis
3 Jiwon Kim: Characteristics and themes of pregnancy-related SUDEP: a registry-based case series using the Epilepsy Deaths Register.
4 Sophia Marsh: Number needed to treat (NNT) for fenfluramine and cannabidiol as add-on treatments for LGS seizures
5 Josie Mayer: Assigned sex and risk of stroke in late onset epilepsy
6 Casey Nash: Valproate prescribing rates amongst women and girls of childbearing age between Welsh primary care clusters
7 Jacob Roelofs: Ultra-rapid VNS titration in Batten’s disease
8 Ben Schroeder: 3MERLIN: Myasthenia, Myositis, Myocarditis syndrome (3M) Epidemiology, Registry founding, and Laboratory INsights
9 Vaishnavi Sharma: The Suspected Cauda Equina Syndrome Score (SuCESS): Development and Validation of a Clinical Triage Tool.
10 Iqra Zia: The Vertigo Challenge: Diagnostic Variability Across Acute Referral Pathways
11 Zhilin Jiang: Diagnosing prodromal synucleinopathies – what is the role of cardiac MIBG scintigraphy?
12 Zhilin Jiang: Haemodynamics of supine graded exercise and orthostatic hypotension in autonomic failure
13 Zhilin Jiang: Pattern and progression of sudomotor dysfunction in alpha synucleinopathies
14 Zhilin Jiang: Peripheral autonomic denervation across domains in patients With normal and abnormal cardiac MIBG
15 Zhilin Jiang: Prominent progressive autonomic failure is a hallmark of Y157X prion protein systemic amyloidosis
Screen 12: General Other
17 Jacqueline Geister: Sprachblockade: Uncommon presentation of myelin oligodendrocyte antibody-associated disease with brainstem predominance and bilingual dysphasia
18 Amira Amsha: Deputyship for families of individuals with epilepsy and intellectual disabilities
19 Saba Arshad: Waking up to the diagnosis of Awakening Ptosis: A case report
20 Solomiia Bandrivska: NFKB1 in Parkinson’s disease: Systematic Review and Multi-Ancestry Genetic Analysis
21 Steven Brown: A novel phenotype associated with IRF2BPL variant: Late-onset cerebellar ataxia and polyneuropathy
22 Elisa Bruno: Burden of Illness Study Among Participants with Central Disorders of Hypersomnolence in the United Kingdom
23 Camille Carroll: EJS ACT-PD: Efficient Roll-out of the Largest-ever Clinical Trial of Treatments to Slow Parkinson’s Progression
24 Camille Carroll: Usability Challenges in Digital Parkinson’s Care: Insights from Clinicians and Patients.
25 Monisha Chakravorty: Access to Cognitive Behavioural Intervention Therapy in Adults with Tourette and Tic Disorders
26 Sanjida Chowdhury: Defining phenotype for MT-TT m.15933G>A: a teenager with MELAS-like phenotype without the canonical MT-TL1m.3243A>G genotype
27 Amber E Corrigan: Phenotypic Variation in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): A Systematic Review
29 Arlene Coulson: Rationalising IVIG Therapy in CIDP: Clinical Outcomes and Cost Impact of a Multidisciplinary Review
30 Lauren Errington: Audit of chronic hydrocephalus patients referred to a regional hydrocephalus MDT in 2024
31 Paola Giunti: The Burden of Friedreich Ataxia in the United Kingdom: Results of an Online Survey
Screen 13: General Other
32 Salika Karunanayaka: Progressive Gait Impairment and Leukodystrophy in a 25-Year-Old Adult with Marked Hyperhomocysteinaemia
33 Cameron Lee: Neurofilament light chain and neutrophil-to-lymphocyte ratio as prognostic biomarkers in Multiple System Atrophy
34 Linda Lei: Towards Biomarker-Driven Staging of Multiple System Atrophy Using Longitudinal Neurofilament Light Profiling
35 Anton Rubiya: Lenin GFAP (glial fibrillary acid protein) astrocytopathy:A mimic of infectious meningo-encephalitis and a pattern to recognise.
36 Haoxuan Li: Culturally Inclusive Assessment of Social Cognition in Primary Brain Tumours Patients
38 Tarek Matar: Freezing Despite Continuous Levodopa Infusion
39 Nikhil Math: Subacute encephalopathy as a sequela of monoclonal antibody therapy
40 Jacob Mistry: Adult-onset progressive dystonia with oculomotor apraxia in TCF20-associated neurodevelopmental disorder
41 Catherine Morgan: TORUS: an Innovative Digital Sensor Platform for Clinical Trial Outcome Measures in Parkinson’s Disease
42 Richard Oguntoye: isolated tongue tremor: A rare focal phenotype of essential tremor
43 Eleanor Owen-Jones: Effect of daridorexant, zolpidem, placebo on wakefulness throughout the night in patients with insomnia disorder
44 Laura Pérez-Carbonell: Efficacy and safety of oveporexton (TAK-861) in narcolepsy type 1 in two phase 3 trials
45 Sangay Phuntsho: Foot Drop Following Rapid Weight Loss: A Case Series and Proposed Mechanisms
46 Isobel Platt: Quantifying Phenotype: A Task-Standardised, Multimodal Protocol for Next-Generation Hyperkinetic Assessment
47 Sanketh Rampes: Improving standards in Botulinum Toxin clinics: a service evaluation of key clinical indicators
Screen 14: General Other / Headache
48 Michael Rushworth: Early UK Real-World Experience with Lecanemab from a private clinic: Safety, Feasibility and Service Implications
49 Vaishnavi Sharma: Does disc consistency matter? A comparative series on calcified and soft thoracic disc herniations
50 Alyssa Shiramba: Changes in tremor, anxiety and depression after MRgFUS for essential tremor: An exploration of predictors
51 Alyssa Shiramba: Multi-target Deep Brain Stimulation for Dystonia and Complex Tremor Syndromes: Case Series and Literature Review
52 Ryan Smith: The Evidence for Epigenetic Age Acceleration in Neurological Disease: A Systematic Review
54 Clara Tierney: Cytokine Release Syndrome-Like Syndrome Following Immune Checkpoint Inhibitor Therapy: A Case Series
55 Muzuki Ueda: Consideration for Device-Aided Therapies in Parkinson’s Disease: A Two-part Audit Using the 5-2-1 Criteria
56 Bhairavi Wijayendran: Serous atrophy of bone marrow from malnutrition with characteristic MRI and novel FDG PET findings
57 Ruth Wood: Amyloid-β pathology disrupts hippocampal spatial coding and oscillatory dynamics in an Alzheimer’s disease mouse model
58 Ruth Wood: The Neurology of Menopause: a review
59 Fatima Zahoor: A Case of Pain, Paralysis and the Journey to Recovery
60 Sathyajith Ambawatte: Low-Pressure Headache Following Rapid Weight Loss Associated with Semaglutide Use
61 Louis Bibby: Efficacy, Safety, and Tolerability of Atogepant for the Acute Treatment of Migraine: ECLIPSE Trial
62 Louis Bibby: Impact of Number of Previous Triptans Trialed on Triptan Effectiveness, Tolerability, and Healthcare Resource Use
63 Louis Bibby: Patient-Reported Outcomes of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: TEMPLE Trial
Screen 15: Headache / Infection / Movement Disorders / MS/Inflammatory
64 Louis Bibby: Safety, Tolerability and Efficacy of Atogepant Added to OnabotulinumtoxinA for Preventive Treatment of Chronic Migraine
65 Louis Bibby: Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine
66 Grant O’Neil: Impact of intake timing on outcomes with rimegepant for acute treatment of migraine in CONFIDENCE
67 Grant O’Neil: Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptans: a 12-week Open-Label Extension.
68 Mark Thaller: Importance of the indometacin trial in short duration trigeminal facial pain
69 Laura White: Headache Coding in Emergency Care: System Constraints, Data Fidelity, and Opportunities for Neurology Pathways
70 Alice Anderton: Understanding Infection Risks with Neurosarcoidosis Treatments
71 Milo Delaney: Infectious spinal cord and root syndromes at Groote Schuur Hospital, Cape Town 2022-2023
72 K K Dey: Cognitive Impairment in HIV with Normal Neuroimaging and CSF: A Case of HIV-Associated Neurocognitive Disorder
73 Liam Hide: The Role of Pro-inflammatory Cytokines in a Model of Neuronal Hyperexcitability Induced by HSV-1 Infection
74 Rebecca Frake: Patterns, prevalence and management of neuropsychiatric symptoms in tertiary atypical parkinsonian syndrome clinic
76 Yassine Noui: Long-term clinical outcomes following rituximab for relapsing-remitting multiple sclerosis in Sweden: a nationwide registry-based study
77 Pavlos Theodorou: Intravenous vs Subcutaneous Natalizumab With Extended Interval Dosing: A Comparison
78 Emily Tregaskis-Daniels: Early Postpartum Experiences in People with Multiple Sclerosis: UK MS Pregnancy Register Data
Screen 16: MS/Inflammatory
79 Hussein Al-Fazly: Progressive Parkinsonism in a Patient with Multiple Sclerosis: An Unexpected Diagnosis of Multiple System-Atrophy
80 Muhammad Saad: Aleem Observational study: Real-world Siponimod tolerability in Secondary Progressive Multiple Sclerosis at a single Neurology centre
81 Tarunya Arun: A National MDT for Neurosarcoidosis: Initial Experience from the NHS England Rare Diseases Collaborative Network
83 Arlene Coulson: Implementation of a Subcutaneous Ocrelizumab (Ocrevus) Home Injection Service: Patient Experience and Service Impact
84 Carolina Dal Bo: Risk of Relapse After Subsequent Pregnancies in Post-Pregnancy Onset MOGAD and NMOSD
85 Nikos Evangelou: T1-Dark Rims Provide a Stand-Alone MRI Marker for Distinguishing Multiple Sclerosis from NMOSD and MOGAD
86 Gavin Giovannoni: Primary Results of the Phase III FENtrepid Study; Fenebrutinib vs Ocrelizumab in Primary Progressive MS
87 Bruno Gran: The association between hormonal contraception and risk of developing multiple sclerosis: Systematic review and meta-analysis
88 Naveed Iqbal: MGUS related CNS inflammation - An Occam’s razor or Hickam’s dictum
89 Nicole Japzon: Novel use of plasma cell-directed immunotherapies for treatment of refractory autoimmune neurological diseases
90 Elizabeth Keen: Age-Related Trends in MRI Activity and DMT Escalation: A Student Audit
91 Yolanda Lau: Influence of comorbid diabetes on outcomes in multiple sclerosis: a UK population-based matched cohort study
92 Christine Masters: Real-world effectiveness of ponesimod in relapsing-remitting MS using the OFSEP cohort
93 Christine Masters: Real-world ponesimod tolerance in France (OFSEP): serious adverse events and post-discontinuation disease activity
94 Joela Mathews: Transforming MS 4 ALL (TMSFA); interactive live website demonstration
Screen 17: MS/Inflammatory
95 Rod Middleton: Emulating a pseudo-trial of Sativex and Baclofen for MS spasticity from the UK MS Register
96 Rod Middleton: Ethnic disparities in Disease Modifying Therapy uptake in Multiple Sclerosis
97 Rod Middleton: Impact of sleep quality over time in people with Multiple Sclerosis
98 Rod Middleton: Post-2020 decline in MS treatments not seen in hypertension / hypercholesterolaemia therapy
99 Suhaib Mohammed: Experience with Cladribine in RRMS Patients at Lancashire Teaching Hospitals NHS Foundation Trust
100 Suhaib Mohammed: Patient’s perspective of subcutaneous Ocrelizumab at Lancashire Teaching Hospital NHS Foundation Trust
101 Richard Oguntoye: Evaluation, avoidance strategies and management of rare neutropenia in MS patients on anti-CD 20 therapies.
102 Richard Oguntoye: Investigating effects of eosinophilia in RRMS patients treated with Cladribine.
103 Dashne Omar: Diagnostic Outcomes from UK National Neurosarcoidosis Multidisciplinary Team
104 Aine Redmond: Clinical, radiological features and management of patients diagnosed with MOGAD: A tertiary referral centre experience.
105 Sandra Saji: The impact of highly effective disease-modifying treatment on hand function and mobility in multiple sclerosis
106 Klaus Schmierer: Attack is back! Testing hyper-acute treatment in people with a first demyelinating event
107 Jack Tallentire: Tumefactive demyelination unresponsive to standard treatment: a case highlighting diagnostic and therapeutic pitfalls
108 Mithila Vijay: Under-Recognised Obstructive Sleep Apnoea Contributes to Cognitive Symptoms in a Multiple Sclerosis Cohort
Screen 18: Neuromuscular / MND
110 Anujh Maharajh: Optimising Early Triage in Motor Neurone Disease: A Quality Improvement Study
111 Nina Tabibzadeh: Remote Monitoring in Myasthenia Gravis: Evaluating HUMA App Utility and Patient Experience
112 Laura White: Developing a Consensus Minimum Data Set for Motor Neurone Disease with Clinicians, Patients and Caregivers
113 Laura Akroyd: Delayed diagnosis and missed opportunities: analysis of the diagnostic journey for LOPD in the UK
114 Tooba Arshad: A metabolic culprit behind diaphragmatic failure
117 Mai Elrayes: Mixed Myopathic–Demyelinating Features Revealing ANO5 Myopathy and CIDP
118 Tanvir Hasan: Expanding The Phenotype of PABPN1 Disease:Genomic Diagnostic Blind Spot in a Complex Neurodegenerative Case
119 Wint Nandar Hein: PABPN1 Repeat Expansion in Atypical Oculopharyngeal Muscular Dystrophy With IBM-like Features
120 Channa Hewamadduma: Phase 3 Design of KYSA-6: Randomized, Controlled Study of Miv-cel CAR-T Versus Standard-of-Care in gMG
121 Maria Isabel Leite: Effect of zilucoplan stratified by age of myasthenia gravis onset: RAISE-XT 120-week post hoc analysis
122 Sharfaraz Salam: Assessing in vivo brain amyloid deposition in inclusion body myositis using positron emission tomography
123 Victoria Saunders: Corticosteroid dose tapering during rozanolixizumab treatment in patients with generalised myasthenia gravis: Post hoc analysis
125 Rami Yammine: Two Genes, One Patient: A complex Neurogenetic Phenotype
Screen 19: Neuromuscular: Peripheral Nerve Epilepsy
126 Fatma Alkolfat: When “CIDP” Rhymes with POEMS: An Osteolytic T12 Lesion and a Demyelinating Mystery
127 Sathyajith Ambawatte: A Pathophysiology-Driven Approach to Reversing Metformin-Induced Neuropathy in a Needle-Phobic Patient
128 Arron Cook: The Conduction-Block Chameleon: Neurolymphomatosis Masquerading as Multifocal Motor Neuropathy
129 Martin Furlepa: A service evaluation of regular subspecialty neuromuscular ward rounds in the Acute Neurology Unit
130 Rebecca Johnson: Atypical Chemotherapy Induced Peripheral Neuropathy: Inflammatory Polyradiculopathy After Tisotumab Vedotin
131 Rebecca Johnson: RECIPe: Replication factor complex 1 repeat Expansions and susceptibility to Chemotherapy Induced Peripheral neuropathy
132 Keng Ming Lau: Early Hyperreflexia in the Acute Motor Axonal Neuropathy Subtype of Guillain–Barré Syndrome
136 AKM Jamiur Rahman: Phenotypic Differences between Symptomatic hATTR Amyloid Neuropathy and Gene Carriers
137 AKM Jamiur Rahman: The West of Scotland experience of Autoimmune Nodo-Paranodopathy in the last 10 years.
138 Dhilmi Suriyarachchi: Investigating the Brachial Plexus: A Quartet of Cases
Screen 20: Quality, Service & Training
139 Asha Bissessar: Croydon Neurology: Triaging of acute neurology (inpatient and Emergency Department) referrals by on-call consultant
140 Osa Eghosa-Aimufua: Prioritising Produodopa Therapy in Parkinson’s Patients:A Quality Improvement Project
141 Ellis Fish: A UK Pilot Registry for Normal Pressure Hydrocephalus: Feasibility and Early Observations
142 Rebecca Johnson: Neurological Examination Before Inpatient Referral: A Multi-Site Audit of Performance and Barriers
143 Daniel Nicholas: Using Large Language Models to perform Clinical Audit
144 Khaizer Rizvi: Socioeconomic inequalities influence treatment escalation and access to specialist Myasthenia Gravis clinics in Greater Manchester
145 Christer Sawaya: Analysis of referral patterns and triage in Southampton and surrounding district hospitals
146 Sam Shribman: The South West London and Surrey neurology pilot: An evaluation of three case-management roles
147 Katherine Stockton: Modelling UK infrastructure and capacity in preparation for disease-modifying treatments in dementia.
148 Kyriakoula Varmpompiti: Paraneoplastic Neurological Syndrome antineuronal antibody testing at a UK University Teaching Hospital
149 Laura White: From Referral to Results: An Enhanced Direct MRI Pathway for Suspected CNS Cancer
150 Laura White: Mapping Practical Neurology to the Neurology Specialty Certificate Examination Curriculum
151 Mya Win: Evaluation of Maintenance IVIG Monitoring and Treatment Optimisation Practices in Immune-Mediated Neuropathies
Email the ABN
Email the Conference Team
abn@phproductionservices.co.uk
Call the ABN
44 (0) 20 7405 4060